Mutation Analysis of Nine Chordoma Specimens by Targeted Next-Generation Cancer Panel Sequencing

• Published in: Journal of Cancer Vol. 6; no. 10; pp. 984 - 989
• Main Authors: Fischer, Carina, Scheipl, Susanne, Zopf, Agnes, Niklas, Norbert, Deutsch, Alexander, Jorgensen, Mette, Lohberger, Birgit, Froehlich, Elke Verena, Leithner, Andreas, Gabriel, Christian, Liegl-Atzwanger, Bernadette, Rinner, Beate
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher 01.01.2015
• Subjects: Research Paper; somatic mutations; cancer panel; chordoma; copy number; next-generation sequencing
• ISSN: 1837-9664; 1837-9664
• DOI: 10.7150/jca.11371

Chordoma is a rare primary malignant bone tumour. Treatment options are mainly restricted to surgical excision, since chordomas are largely resistant to conventional ionising radiation and chemotherapy. Thus, there is a strong need to gain more thorough insights into the molecular biology and genetics of chordoma to allow for the development of new therapeutic options. We performed an ultra-deep sequencing analysis to find novel mutations in cancer associated genes in chordomas to date unseen with Sanger sequencing. Nine chordomas (skull base (n=3), mobile spine (n=4), and sacrum/coccyx (n=2) were screened for mutations in 48 cancer genes using the Hot Spot Cancer Panel (Illumina). All putative mutations were compared against multiple databases (e.g. NCBI, COSMIC, PolyPhen, EGB, SIFT) and published Copy Number Variation (CNV) data for chordoma. Our results showed mutations with a frequency above 5% in tumorsuppressor- and onco-genes, revealing new possible driver genes for chordomas. We detected three different variants accounting for 11 point mutations in three cancer associated genes (KIT, KDR and TP53). None of the detected mutations was found in all samples investigated. However, all genes affected interact or are connected in pathway analysis. There were no correlations to already reported CNVs in the samples analysed. We identified mutations in the associated genes KIT, KDR, and TP53. These mutations have been described previously and have been predicted to be tolerated. Further results on a larger series are warranted. The driver mechanisms of chordoma still have to be identified.